Cargando…

Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials

INTRODUCTION: Controversy regarding optimum duration of trastuzumab treatment remains in patients with human epidermal growth factor receptor-2 (HER2) positive early breast cancer. The objective of applying network meta-analysis (NMA) is to integrate existing evidence based on direct and indirect co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Qiancheng, Wang, Xin, Chen, Ye, Li, Xiaofen, Luo, Ting, Cao, Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682472/ https://www.ncbi.nlm.nih.gov/pubmed/33444169 http://dx.doi.org/10.1136/bmjopen-2019-035802

Ejemplares similares

Optimum adjuvant trastuzumab duration for human epidermal growth factor receptor-2 positive breast cancer: a network meta-analysis of randomized trials
por: Ma, Ji, et al.
Publicado: (2021)

Optimum duration of extended adjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: protocol for a network meta-analysis of randomised controlled trials
por: Hu, Qiancheng, et al.
Publicado: (2023)

Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer
por: Yu, Ke-Da, et al.
Publicado: (2020)

Case Report: Trastuzumab Treatment in Adenosquamous Carcinoma of the Extrahepatic Biliary Tract With Her-2 Amplification
por: Hong, Ye, et al.
Publicado: (2021)

Optimal dose-fractionation schedule of palliative radiotherapy for patients with bone metastases: a protocol for systematic review and network meta-analysis
por: Tang, Xiaofang, et al.
Publicado: (2020)

Role of CDK4/6 inhibitors in patients with hormone receptor (HR)-positive, human epidermal receptor-2 negative (HER-2) metastatic breast cancer study protocol for a systematic review, network meta-analysis and cost-effectiveness analysis
por: Hu, Qiancheng, et al.
Publicado: (2022)

Which is the optimal adjuvant chemotherapy for resected pancreatic ductal adenocarcinoma?: A protocol for a network meta-analysis of randomized controlled trials
por: Hu, Qiancheng, et al.
Publicado: (2019)

The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers
por: Kim, Hye Ryeon, et al.
Publicado: (2021)

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK
por: Earl, H.M., et al.
Publicado: (2021)

Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials
por: Xu, Zhi-qiao, et al.
Publicado: (2017)

Factors Influencing Adjuvant Chemotherapy and Trastuzumab Choice in Older Human Epidermal Growth Factor Receptor 2-positive Breast Cancer Patients
por: Fang, Yan, et al.
Publicado: (2020)

miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer
por: Nielsen, Boye Schnack, et al.
Publicado: (2014)

Adjuvant Trastuzumab Is Required in Human Epidermal Growth Factor Receptor 2-Positive Node-Negative Breast Cancer Patients Regardless of Tumour Size
por: Bender, Laura, et al.
Publicado: (2020)

Efficacy and survival of anti-PD-1 antibody in combination with trastuzumab and chemotherapy versus trastuzumab and chemotherapy as first-line treatment of HER2-positive metastasis gastric adenocarcinoma: a retrospective study
por: Deng, Ting, et al.
Publicado: (2023)

Six Months vs. 12 Months of Adjuvant Trastuzumab Among Women With HER2-Positive Early-Stage Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Deng, Huan, et al.
Publicado: (2020)

Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis protocol
por: Lv, Wanrui, et al.
Publicado: (2022)

Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials
por: Liu, Xiaoyun, et al.
Publicado: (2022)

Case Report: Herceptin as a Potentially Valuable Adjuvant Therapy for a Patient With Human Epidermal Growth Factor Receptor 2-Positive Advanced Esophageal Squamous Cell Carcinoma
por: Han, Li, et al.
Publicado: (2021)

Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
por: Li, Yi, et al.
Publicado: (2020)

Role of maintenance strategies in advanced epithelial ovarian cancer: a systematic review, network meta-analysis and cost-effectiveness analysis protocol
por: Hu, Qiancheng, et al.
Publicado: (2021)

Trastuzumab-Induced Interstitial Pneumonitis
por: Errisuriz, Kimberly, et al.
Publicado: (2023)

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study
por: Gligorov, Joseph, et al.
Publicado: (2022)

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
por: Wang, Zhen-hao, et al.
Publicado: (2022)

Hypofractionated versus conventional intensity-modulated radiation irradiation (HARVEST-adjuvant): study protocol for a randomised non-inferior multicentre phase III trial
por: Xie, Jinrong, et al.
Publicado: (2022)

First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study
por: Li, Xiaofen, et al.
Publicado: (2022)

Concurrent administration of trastuzumab and anthracyclines as adjuvant regimen for HER2-positive breast cancer: a randomised controlled trial
por: Shen, Songjie, et al.
Publicado: (2017)

An optimum LEP position
por: Plass, Günther
Publicado: (1982)

Multicentre, randomised controlled trial of adjuvant chemotherapy in cervical cancer with residual human papilloma virus DNA following primary radiotherapy or chemoradiotherapy: a study protocol
por: Wang, Yanhong, et al.
Publicado: (2019)

ERBB2D16 Expression in HER2 Positive Gastric Cancer Is Associated With Resistance to Trastuzumab
por: Wang, Shuo, et al.
Publicado: (2022)

Imaging Findings From Different Pathological Types of Oral and Maxillofacial Intramuscular Hemangiomas for Selecting Optimum Management
por: Zhu, Dan, et al.
Publicado: (2022)

Corticosteroids for COVID-19: the search for an optimum duration of therapy
por: Mishra, Gyanshankar P, et al.
Publicado: (2021)

High Systemic Immune-Inflammation Index Predicts Poor Survival in Patients with Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Receiving Adjuvant Trastuzumab
por: Jiang, Li, et al.
Publicado: (2020)

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients
por: Guo, Jihong, et al.
Publicado: (2019)

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
por: Bae, Soong June, et al.
Publicado: (2021)

Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
por: Larionov, Alexey A.
Publicado: (2018)

Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis
por: Zhu, Youwen, et al.
Publicado: (2022)

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
por: Noda-Narita, Shoko, et al.
Publicado: (2019)

Trastuzumab Emtansine for the Treatment of HER-2 Positive Carcinoma Ex-pleomorphic Adenoma Metastatic to the Brain: A Case Report
por: Hassanieh, Ihab, et al.
Publicado: (2018)

Intrathecal trastuzumab for leptomeningeal carcinomatosis in patients with human epidermal growth factor receptor 2 positive breast cancer
por: Gulia, Seema, et al.
Publicado: (2016)

Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer
por: Conte, PierFranco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mjhmpg6c00dbq27gii4ub86qir